EDAP TMS Pre-Announces Strong 98% Growth in HIFU sales in the Second Quarter 2019
EDAP TMS Pre-Announces Strong 98% Growth in HIFU sales in the Second Quarter 2019
- 45% growth in total Q2 2019 revenue year-over-year
- 78% growth in HIFU sales year-to-date through
June 30, 2019
- Company to Report Second Quarter 2019 Financial Results on
Wednesday, August 28, 2019 and to host conference call and webcast onThursday August 29 , at8:30 am EDT
Preliminary total revenue for the second quarter 2019 totaled
Year-to-date through
An accompanying conference call and webcast will be conducted by management to review the results. The call will be held at 8:30am EDT on Thursday, August 29, 2019. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast
Domestic: 877-451-6152
International: 201-389-0879
Passcode: 13693076
Webcast: http://public.viavid.com/index.php?id=135590
About
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the
Company Contact
Investor Relations / Legal Affairs
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
Source: EDAP TMS S.A.